Loading...
XSHG
600211
Market cap1.76bUSD
Jul 10, Last price  
38.03CNY
1D
-1.25%
1Q
-12.19%
Jan 2017
-4.03%
Name

Tibet Rhodiola Pharmaceutical Holding Co

Chart & Performance

D1W1MN
XSHG:600211 chart
P/E
13.07
P/S
4.15
EPS
2.91
Div Yield, %
5.04%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
16.53%
Revenues
2.95b
+5.13%
861,841,830823,238,000991,069,9641,109,621,0751,110,729,0001,079,038,0001,221,385,4211,402,221,1581,668,036,0411,382,755,815796,806,691915,625,7171,027,879,2091,256,021,9571,373,105,1052,138,586,5522,554,609,0653,134,328,3492,806,713,2952,950,579,806
Net income
938m
-10.78%
4,086,944-125,269,0006,486,26420,203,24023,557,00020,514,00030,530,18527,153,18420,979,87991,635,776198,289,481229,645,755215,606,217312,321,260418,095,836208,938,070369,839,850800,913,9891,051,288,313937,931,435
CFO
1.03b
+3.21%
33,630,000-18,295,00021,457,00017,884,0001,900,16912,090,45256,201,000279,222,000-141,403,000133,930,000250,205,00091,457,000289,217,000489,592,000428,166,000366,531,000837,377,0001,082,138,000994,791,0001,026,716,149
Dividend
Sep 01, 20250.881 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products. In addition, the company offers biopharmaceuticals, traditional Chinese medicine, and chemical drugs for various fields, such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines. The company was founded in 1999 and is headquartered in Lhasa, China.
IPO date
Jul 21, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT